Month: January 2024

Energy Industry Report – Energy Stocks Fell Alongside Energy Prices But Remain Attractive Investments

Posted on by cpatches

This image has an empty alt attribute; its file name is image-1-1024x232.png

Friday, January 5, 2024

Michael Heim, CFA, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the bottom of the report for important disclosures

Energy stocks declined in the fourth quarter in response to falling energy prices. Energy stocks declined 7.2% during the 2023 fourth quarter. The movement of the XLE is similar to that of near-month oil future prices.

Oil prices declined sharply in the fourth quarter after a runup in the third quarter. West Texas Intermediate oil prices declined 21.1% in the fourth quarter to $71.65 per barrel. Domestic oil production continues to grow (up 7% year over year through October) even as the number of domestic oil rigs has decreased 20% since this time last year. Natural gas prices declined 14.2% during the quarter to $2.51 per thousand cubic feet (mcf) of gas. Weather was 13% warmer than normal in the December quarter. As a result, natural gas storage levels are at five-year seasonally high levels as they have been for the last twelve months. 

Merger Activity is heating up. More than $100 billion in acquisitions were announced in the last three months as APA, Exxon Mobil and Chevron all announced transactions. The acquisitions come as major energy companies seek to expand production during a period when production growth from technological improvements seems to be slowing. 

Energy Companies continue to generate high cash levels at current energy prices. Despite the drop in energy prices, operating netbacks (revenues less royalties and operating costs) remain high. With debt levels low, energy managements have raised capital budgets, increased dividends, and repurchased shares. 

Valuations remain attractive. With the decline in energy company stock values, many companies are trading at enterprise values that are less than five times free cash flow. Given our belief that energy prices are entering a period of relative stability (oil prices trade in a range of $60-$10/bbl) and that stock prices have already reacted to energy price declines to the lower end of this range, we see limited downside to investing in energy stocks and large upside should energy prices rise.

Energy stocks declined in the fourth quarter in response to falling energy prices.

Energy stocks, as measured by the Energy Select Sector SPDR Fund (XLE) declined 7.2% during the 2023 fourth quarter. The decline stands in sharp contrast to an 11.2% increase in the S&P Composite index. The decline in the XLE began early with the index dropping almost 10% in the first week of the quarter before regaining its losses in the next two weeks. After peaking on October 18th, the index fell sharply over the next two months and never recovered from its losses. The movement of the XLE is similar to that of near-month oil future prices.

Oil prices declined sharply in the fourth quarter after a runup in the third quarter.

West Texas Intermediate oil prices declined 21.1% in the fourth quarter to $71.65 per barrel, offsetting a 30.0% increase in the third quarter. For the year, WTI declined 10%. The oil price spikes of 2022 that sent prices above $120 per barrel shortly after Russia invaded Ukraine seem a distant memory. Energy production disruptions and political sanctions have changed the direction of the flow of energy but not the overall global demand and supply of energy. We are keeping an eye on political developments in the Red Sea, but to date there has been little impact on oil prices. Domestic oil production continues to grow (up 7% year over year through October) even as the number of domestic oil rigs has decreased 20% since this time last year. The biggest decline has been in the Permian Basin. Almost all wells being drilled are now horizontal wells.

The decline in natural gas prices was not as sharp and was largely explained by warm weather.

Natural gas prices declined 14.2% during the quarter to $2.51 per thousand cubic feet (mcf) of gas. After sharp spikes in 2022, natural gas prices have settled into a narrow range between $2.00/mcf and $3.00/mcf. Weather was 13% warmer than normal on a population-weighted basis in the December quarter. As a result, natural gas storage levels are at five-year seasonally high levels as they have been for the last twelve months. Gas production continues to increase steadily, mainly to feed an increased demand for natural gas for power generation.

Merger Activity is heating up.

On January 4, 2024, APA Corporation, parent of Apache Corporation, agreed to acquire Callon Petroleum for approximately $4.5 billion in a stock-swap deal. The acquisition follows Exxon Mobil’s $59.5 billion agreement to buy Pioneer Natural Resources and Chevron’s $53 billion deal to buy Hess Corporation in October 2023. The acquisitions come as major energy companies seek to expand production during a period when production growth from technological improvements seems to be slowing. The acquisitions, while all three stock transactions, may also represent improved balance sheets and cash flow. As we have discussed in the past, energy companies have used recent energy price upcycles to pay down debt and repurchase shares as opposed to previous cycles when management expanded drilling efforts that eventually drove down energy prices. The result has been more muted energy price cycles that extend for longer periods of time.

Energy Companies continue to generate high cash levels at current energy prices.

Despite the drop in energy prices, operating netbacks (revenues less royalties and operating costs) remain high. With debt levels low, energy management have raised capital budgets, increased dividends, and repurchased shares. Management is always reluctant to raise dividends to levels that are unsustainable in a down cycle. As a result several energy companies have begun to institute special dividends. We expect manage to continue to invest in growth and reward shareholders even at current energy levels. Should energy prices rise, these activities should accelerate.

Valuations remain attractive.

With the decline in energy company stock values, many companies are trading at enterprise values that are less than five times free cash flow. We view this multiple as unsustainable given an increased use of cash flow to repurchase shares. This is especially true of companies with slow production decline curves such as the companies we follow in western Canada. Given our belief that energy prices are entering a period of relative stability (oil prices trade in a range of $60-$10/bbl) and that stock prices have already reacted to energy price declines to the lower end of this range, we see limited downside to investing in energy stocks and large upside should energy prices rise. We believe this is especially true for smaller cap energy stocks that have ample drilling opportunities and that could be takeover targets for larger energy companies that do not.

GENERAL DISCLAIMERS

All statements or opinions contained herein that include the words “we”, “us”, or “our” are solely the responsibility of Noble Capital Markets, Inc.(“Noble”) and do not necessarily reflect statements or opinions expressed by any person or party affiliated with the company mentioned in this report. Any opinions expressed herein are subject to change without notice. All information provided herein is based on public and non-public information believed to be accurate and reliable, but is not necessarily complete and cannot be guaranteed. No judgment is hereby expressed or should be implied as to the suitability of any security described herein for any specific investor or any specific investment portfolio. The decision to undertake any investment regarding the security mentioned herein should be made by each reader of this publication based on its own appraisal of the implications and risks of such decision.

This publication is intended for information purposes only and shall not constitute an offer to buy/sell or the solicitation of an offer to buy/sell any security mentioned in this report, nor shall there be any sale of the security herein in any state or domicile in which said offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or domicile. This publication and all information, comments, statements or opinions contained or expressed herein are applicable only as of the date of this publication and subject to change without prior notice. Past performance is not indicative of future results. Noble accepts no liability for loss arising from the use of the material in this report, except that this exclusion of liability does not apply to the extent that such liability arises under specific statutes or regulations applicable to Noble. This report is not to be relied upon as a substitute for the exercising of independent judgement. Noble may have published, and may in the future publish, other research reports that are inconsistent with, and reach different conclusions from, the information provided in this report. Noble is under no obligation to bring to the attention of any recipient of this report, any past or future reports. Investors should only consider this report as single factor in making an investment decision.

IMPORTANT DISCLOSURES

This publication is confidential for the information of the addressee only and may not be reproduced in whole or in part, copies circulated, or discussed to another party, without the written consent of Noble Capital Markets, Inc. (“Noble”). Noble seeks to update its research as appropriate, but may be unable to do so based upon various regulatory constraints. Research reports are not published at regular intervals; publication times and dates are based upon the analyst’s judgement. Noble professionals including traders, salespeople and investment bankers may provide written or oral market commentary, or discuss trading strategies to Noble clients and the Noble proprietary trading desk that reflect opinions that are contrary to the opinions expressed in this research report.
The majority of companies that Noble follows are emerging growth companies. Securities in these companies involve a higher degree of risk and more volatility than the securities of more established companies. The securities discussed in Noble research reports may not be suitable for some investors and as such, investors must take extra care and make their own determination of the appropriateness of an investment based upon risk tolerance, investment objectives and financial status.

Company Specific Disclosures

The following disclosures relate to relationships between Noble and the company (the “Company”) covered by the Noble Research Division and referred to in this research report.
Noble is not a market maker in any of the companies mentioned in this report. Noble intends to seek compensation for investment banking services and non-investment banking services (securities and non-securities related) with any or all of the companies mentioned in this report within the next 3 months

ANALYST CREDENTIALS, PROFESSIONAL DESIGNATIONS, AND EXPERIENCE

Senior Equity Analyst focusing on Basic Materials & Mining. 20 years of experience in equity research. BA in Business Administration from Westminster College. MBA with a Finance concentration from the University of Missouri. MA in International Affairs from Washington University in St. Louis.
Named WSJ ‘Best on the Street’ Analyst and Forbes/StarMine’s “Best Brokerage Analyst.”
FINRA licenses 7, 24, 63, 87

WARNING

This report is intended to provide general securities advice, and does not purport to make any recommendation that any securities transaction is appropriate for any recipient particular investment objectives, financial situation or particular needs. Prior to making any investment decision, recipients should assess, or seek advice from their advisors, on whether any relevant part of this report is appropriate to their individual circumstances. If a recipient was referred to Noble Capital Markets, Inc. by an investment advisor, that advisor may receive a benefit in respect of
transactions effected on the recipients behalf, details of which will be available on request in regard to a transaction that involves a personalized securities recommendation. Additional risks associated with the security mentioned in this report that might impede achievement of the target can be found in its initial report issued by Noble Capital Markets, Inc.. This report may not be reproduced, distributed or published for any purpose unless authorized by Noble Capital Markets, Inc..

RESEARCH ANALYST CERTIFICATION

Independence Of View
All views expressed in this report accurately reflect my personal views about the subject securities or issuers.

Receipt of Compensation
No part of my compensation was, is, or will be directly or indirectly related to any specific recommendations or views expressed in the public
appearance and/or research report.

Ownership and Material Conflicts of Interest
Neither I nor anybody in my household has a financial interest in the securities of the subject company or any other company mentioned in this report.

Great Lakes Dredge & Dock (GLDD) – A “Reset” on Empire II

Posted on by cpereira@noblefcm.com


Friday, January 05, 2024

Great Lakes Dredge & Dock Corporation is the largest provider of dredging services in the United States. In addition, Great Lakes is fully engaged in expanding its core business into the rapidly developing offshore wind energy industry. The Company has a long history of performing significant international projects. The Company employs experienced civil, ocean and mechanical engineering staff in its estimating, production and project management functions. In its over 131-year history, the Company has never failed to complete a marine project. Great Lakes owns and operates the largest and most diverse fleet in the U.S. dredging industry, comprised of approximately 200 specialized vessels. Great Lakes has a disciplined training program for engineers that ensures experienced-based performance as they advance through Company operations. The Company’s Incident-and Injury-Free® (IIF®) safety management program is integrated into all aspects of the Company’s culture. The Company’s commitment to the IIF® culture promotes a work environment where employee safety is paramount.

Joe Gomes, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

A Termination. Coming as no surprise, European energy firms Equinor and BP announced an agreement with the New York State Energy Research and Development Authority to terminate the Offshore Wind Renewable Energy Certificate Agreement for the Empire Wind II project. As we previously noted, rising inflation, higher borrowing costs, and supply chain issues combined to negatively impact potential returns from the project. Termination of the Empire Wind II project initiates a contractually obligated termination fee payable to Great Lakes and Van Oord that is intended to cover lost earnings potential related to Empire Wind II.

But A Reset. But all is not lost, as Equinor and BP can re-submit the project on more acceptable terms. With the state supporting offshore wind projects, we believe there remains a strong chance the project is revived in some form. Winners of an expedited solicitation for offshore wind will be announced in February.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Bit Digital (BTBT) – December BTC Production Increases 19%

Posted on by cpereira@noblefcm.com


Friday, January 05, 2024

Joe Gomes, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Production. During the month of December, Bit Digital produced 169.5 BTC, a 19% increase compared to the prior month. Active hash rate as of December 31st was approximately 2.52 EH/s, up from 2.25 EH/s as of November 30, 2023, and well on the way to the new goal of  doubling the operating fleet in the Bitcoin mining operations, to approximately 6.0 EH/s, during 2024.

Staking. Bit Digital had approximately 12,752 ETH actively staked in native and liquid staking protocols as of December 31, 2023, down slightly from 12,784 at the end of November. Approximately 12,352 ETH were natively staked and 400 ETH were deployed in liquid staking protocols as of that date. The Company earned a blended APY of approximately 3.67% on its staked ETH position for the month, down from 4.35% in November, and earned aggregate staking rewards of approximately 38.5 ETH.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Strong December Jobs Report Challenges Expectations of Imminent Fed Rate Cuts

Posted on by slightbourne@noblecapitalmarkets.com

The Labor Department’s December jobs report reveals continued strength in the U.S. economy that defies expectations of an imminent slowdown. Employers added 216,000 jobs last month, handily beating estimates of 170,000. The unemployment rate remained low at 3.7%, contrary to projections of a slight uptick.

This hiring surge indicates the labor market remains remarkably resilient, even as the Federal Reserve wages an aggressive battle against inflation through substantial interest rate hikes. While many anticipated slowing job growth at this stage of the economic cycle, employers continue adding workers at a solid clip.

Several sectors powered December’s payroll gains. Government employment rose by 52,000, likely reflecting hiring for the 2024 Census. Healthcare added 38,000 jobs across ambulatory care services and hospitals, showing ongoing demand for medical services. Leisure and hospitality contributed 40,000 roles, buoyed by Americans’ continued willingness to dine out and travel.

Notable gains also emerged in social assistance (+21,000), construction (+17,000), and retail (+17,000), demonstrating broad-based labor market vitality. Transportation and warehousing shed 23,000 jobs, a rare weak spot amid widespread hiring.

Just as importantly, wage growth remains elevated, with average hourly earnings rising 0.4% over November and 4.1% year-over-year. This exceeds projections, signaling ongoing inflationary pressures in the job market as employers compete for talent. It also challenges hopes that wage growth would start moderating.

Financial markets reacted negatively to the jobs data, with stock index futures declining sharply and Treasury yields spiking. The strong hiring and wage numbers dampen expectations for the Fed to begin cutting interest rates in the first half of 2023. Traders now see reduced odds of a rate cut at the March policy meeting.

This report paints a picture of an economy that is far from running out of steam. Despite the steepest interest rate hikes since the early 1980s, businesses continue adding jobs at a healthy pace. Consumers keep spending as well, with holiday retail sales estimated to have hit record highs.

Meanwhile, GDP growth looks solid, inflation has clearly peaked, and the long-feared recession has yet to materialize. Yet the Fed’s priority is returning inflation to its 2% target. With the job market still hot, the path to lower rates now appears more arduous than markets anticipated.

The data supports the notion that additional rate hikes may be necessary to cool economic activity and tame inflation. However, the Fed also wants to avoid triggering a recession through overtightening, making its policy stance a delicate balancing act.

For most of 2023, the central bank enacted a series of unusually large 0.75 percentage point rate increases. But it downshifted to a 0.5 point hike in December, and markets once priced in rate cuts starting as early as March 2024. This jobs report challenges that relatively dovish stance.

While inflation is clearly off its summertime highs, it remains well above the Fed’s comfort zone. Particularly concerning is the continued strong wage growth, which could fuel further inflation. Businesses will likely need to pull back on hiring before the wage picture shifts significantly.

Despite market hopes for imminent rate cuts, the Fed has consistently stressed the need to keep rates elevated for some time to ensure inflation is well and truly tamed. This data backs up the central bank’s more hawkish messaging in recent weeks.

The strong December jobs numbers reinforce the idea that the economy enters 2024 on solid ground, though facing uncertainties and challenges on the path ahead. With inflation still lingering and the full impacts of rising interest rates yet to be felt, the road back to normalcy remains long.

For policymakers, the report highlights the delicate balancing act between containing prices and maintaining growth. Cooling the still-hot labor market without triggering a downturn will require skillful and strategic policy adjustments informed by data like this jobs report.

While markets may hope for a swift policy pivot, the Fed is likely to stay the course until inflation undeniably approaches its 2% goal on a sustained basis. That day appears further off after this robust jobs data, meaning businesses and consumers should prepare for more rate hikes ahead.

Microchip Secures $162M in Federal Funding to Amplify U.S. Chip Production Capacities

Posted on by slightbourne@noblecapitalmarkets.com

The U.S. government is making a strategic $162 million bet on accelerating domestic semiconductor manufacturing capabilities through a major grant for Microchip Technology. The move aims to strengthen supply chain security for critical technologies while reducing dependence on overseas chip production.

Announced by the Department of Commerce, the funding will help Microchip Technology significantly expand output of mature-node semiconductors and microcontroller units at two fabrication plants in the United States.

The boosted stateside capacity for these legacy chips, used across autos, consumer devices, telecom infrastructure, aerospace and defense, is a core tenet of the Biden administration’s “Chips for America” initiative to rebuild domestic chipmaking.

For investors, the government subsidization provides a buffer against supply shocks in key end-markets for Microchip and peers specializing in current-generation chips. The build-out of U.S. semiconductor infrastructure also unlocks new revenue opportunities associated with “onshoring” trends.

Strategic Tech Security Play

The $162 million grant, which still requires finalization, represents the second major award under the Chips for America program passed by Congress in 2022. The legislation allocated $52.7 billion towards strengthening U.S. semiconductor R&D and manufacturing.

The hefty government funding aims to insulate the U.S. from the global chip shortages and supply chain disruptions experienced during the pandemic, which rippled across the auto sector, consumer appliance makers, and other key domestic industries.

“The award will help reduce reliance on global supply chains that led to price spikes and long wait lines for everything from autos to washing machines during the pandemic,” said Lael Brainard, Director of the White House National Economic Council.

The U.S. chip funding arrives amid mounting concern over economic and national security risks associated with foreign chipmaking dominance. America now accounts for only 12% of worldwide semiconductor manufacturing, down from 37% in 1990, according to SIA data. Meanwhile, East Asia now represents 75% of fabrication, led by Taiwan at 92% of the advanced chips market.

As chips become more vital for technologies like EVs, 5G, and AI, U.S. officials seek to curb dependence on overseas production capacity to ensure domestic tech leadership. The risks became evident as COVID-related shutdowns drove severe chip shortages.

Doubling Down on Legacy Chip Lines

The direct grants to Microchip Technology will expand legacy chip production at the firm’s factories in Colorado and Oregon. Microchip specializes in microcontroller, analog, and flash memory chips used in everything from cars to defense systems.

The $90 million Colorado facility investment will triple output of 8-inch wafers for mature-node integrated circuits. The $72 million Oregon fab funding will double microcontroller manufacturing.

The ramped up legacy chip capacities reinforce Microchip’s competitive position as demand intensifies for current-generation semiconductors across tech and automotive. The expansions build on the firm’s January announcement of an $800 million investment to triple Oregon fab output.

For investors, the state support helps de-risk Microchip’s domestic production scale-up amid turbulent macroeconomic conditions and provides a backstop as management executes its capacity roadmap.

The funding also spotlights the ongoing critical role of mature node chips, even as leading-edge semiconductors grab headlines. While crucial for advanced chips, restoring U.S. leadership in legacy nodes directly serves major industries where shortages have hammered bottom lines.

First Moves in U.S. Chip Reshoring

The planned Microchip award marks an early win under the broader Chips and Science Act Passed by Congress. The bipartisan legislation codified semiconductor manufacturing and R&D funding as a strategic priority, authorizing $52 billion in incentives.

The law sets aside $39 billion in semiconductor manufacturing subsidies, $11 billion for R&D, and $2 billion for legacy chip production – recognizing the outsized importance of lagging U.S. capacities in mature node manufacturing.

The Microchip grants constitute the second such funding award under the Act, following $35 million granted in December to a BAE Systems semiconductor facility that produces chips for defense platforms.

But this represents merely the tip of the iceberg, with Commerce Secretary Gina Raimondo forecasting about a dozen total semiconductor subsidy awards in 2024 potentially worth billions each. The incoming wave of sizeable incentives promises to radically reshape the domestic chipmaking landscape.

For institutional investors, the government initiatives lend viability to plans from Intel, Micron, and other U.S. firms to build large-scale domestic fabrication plants. The investments will drive growth while reducing exposure to offshore production risks.

The amplified U.S. chipmaking capacities will also benefit semiconductor equipment providers and material/gas suppliers up and down the supply chain. As the push accelerates in 2023 and 2024, investors have an opportunity to position for the resshoring trend.

Overall, the expansion of U.S. chip fabrication driven by the incoming subsidies provides a long-term structural tailwind. With semiconductors only becoming more indispensable, boosting domestic manufacturing enhances the tech independence and leadership vital for national security interests. The Microchip awards represent an early step on the path towards reclaiming domestic chip dominance.

Release – GeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients

Posted on by aweinsoff@channelchek.com

Research News and Market Data on GOVX

 

Therapy Demonstrated Safety, Stabilization/Shrinkage of Treated Tumors

Expanded Development for Monotherapy and Combination Therapy Anticipated

Atlanta, GA, January 4, 2024 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the closure of patient enrollment for the Phase 1/2 clinical study evaluating Gedeptin® in patients suffering from advanced head and neck cancer.

Kelly McKee, MD, MPH, GeoVax’s Chief Medical Officer stated, “Completion of this trial will be a significant milestone in our Gedeptin clinical development program. Allowing time for the maximum number of cycles of Gedeptin therapy and patient follow-up, we expect to complete the study by the third quarter of this year. In the interim, we are in active discussions with advisors on protocol development in support of a follow-on Phase 2 or Phase 2/3 trial among patients with advanced head and neck cancer in whom current therapeutic options are suboptimal.  Our intent is to discuss this follow-on protocol with the FDA, in conjunction with a complete review of the results of the current trial, to ensure alignment with the regulator’s expectations.  We expect that such discussions will include addressing the opportunity and basis for an expedited approval pathway.”

Dr. McKee continued, “Demonstrating the safety, tolerability, and stabilization or shrinkage of injected tumors in patients receiving multiple cycles of Gedeptin opens the door to advancing this promising therapeutic in additional patients with advanced head and neck cancer as well as in patients with other solid tumor types and at multiple points in their therapeutic journey.”

David Dodd, GeoVax’s Chairman and CEO, commented, “We believe that the successful completion of the current trial, in conjunction with earlier findings from the completed Phase 1 first-in-human trial and preclinical investigations, provide a sound rationale for proceeding with further Gedeptin investigations.  These will include adjustments to the Gedeptin treatment regimen and combination with immune checkpoint inhibitors in advanced head and neck cancer as well as for additional cancerous and non-cancerous tumor indications. These advances represent a significant potential opportunity for GeoVax to improve the performance of immune checkpoint inhibitors and/or introduce Gedeptin as a treatment option in patients with earlier-stage disease.”

About Gedeptin®

Gedeptin is a novel patented product/technology for the treatment of solid tumors through a gene therapy strategy known as Gene-Directed Enzyme Prodrug Therapy (GDEPT). In GDEPT, a vector is used to selectively transduce tumor cells with a nonhuman gene, which expresses an enzyme that can convert a nontoxic prodrug into a very toxic antitumor compound in situ.

The ongoing Phase 1/2 trial (ClinicalTrials.gov Identifier: NCT03754933) is evaluating the safety and efficacy of repeat cycles of Gedeptin therapy in patients with recurrent head and neck squamous cell carcinoma (HNSCC), with tumor(s) accessible for injection and no curable treatment options. The protocol entails up to five treatment cycles, each consisting of three intratumoral injections of Gedeptin over two days followed by infusion of a prodrug, fludarabine phosphate, once a day for three days. A completed Phase 1 dose-ranging study demonstrated that treating a tumor with a single cycle of Gedeptin, followed by fludarabine infusions, was well tolerated, with evidence of a reduction in tumor size in patients with solid tumors.

A previously reported interim data review demonstrated:

  • No dose limiting toxicities or serious adverse events (SAEs) are definitively attributable to treatment. Additionally, no adverse events above grade 3 severity have been reported.
  • Up to 5 cycles of Gedeptin treatment have been administered without limiting sequelae. Intratumoral expression of the PNP transgene by RT-PCR has been established in treated tumors studied to date.
  • Impairment of tumor growth (i.e., “stable disease” using RECIST 1.1 evaluation criteria) in targeted lesions was seen in 5 of 7 patients; tumor response assessment in one patient remains under study.

The current study is being funded in part by the FDA pursuant to its Orphan Products Clinical Trials Grants Program.  The FDA has also granted Gedeptin orphan drug status for the intratumoral treatment of anatomically accessible oral and pharyngeal cancers, including cancers of the lip, tongue, gum, floor of mouth, salivary gland, and other oral cavities.

About GeoVax

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel therapies and vaccines for solid tumor cancers and many of the world’s most threatening infectious diseases. The company’s lead program in oncology is a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, presently in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax’s lead infectious disease candidate is GEO-CM04S1, a next-generation COVID-19 vaccine targeting high-risk immunocompromised patient populations. Currently in three Phase 2 clinical trials, GEO-CM04S1 is being evaluated as a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, and as a booster vaccine in patients with chronic lymphocytic leukemia (CLL). In addition, GEO-CM04S1 is in a Phase 2 clinical trial evaluating the vaccine as a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. GeoVax has a leadership team who have driven significant value creation across multiple life science companies over the past several decades. For more information, visit our website: www.geovax.com.

Forward-Looking Statements

This release contains forward-looking statements regarding GeoVax’s business plans. The words “believe,” “look forward to,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax’s immuno-oncology products and preventative vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax’s viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventative vaccines with the desired characteristics in a timely manner, GeoVax’s immuno-oncology products and preventative vaccines will be safe for human use, GeoVax’s vaccines will effectively prevent targeted infections in humans, GeoVax’s immuno-oncology products and preventative vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax’s products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control.

Further information on our risk factors is contained in our periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. 

Company Contact:                  Investor Relations Contact:                  Media Contact:
info@geovax.com paige.kelly@sternir.com sr@roberts-communications.com 
678-384-7220 212-698-8699 202-779-0929

Release – ISG Launches Suite of Applied AI Advisory Services

Posted on by aweinsoff@channelchek.com

Research News and Market Data on III

1/4/2024

Firm plans to leverage its longstanding expertise in technology sourcing and governance to help enterprise clients adopt AI at scale

STAMFORD, Conn.–(BUSINESS WIRE)– Information Services Group (ISG) (Nasdaq: III), a leading global technology research and advisory firm, has launched a new suite of advisory services to help clients navigate the complexities and implications of adopting artificial intelligence at scale.

“Artificial Intelligence, specifically Generative AI, is the next big thing in technology,” said Michael P. Connors, chairman and CEO of ISG. “Gen AI has risen to the top of the agenda for the world’s largest corporations. Business leaders are already seeking our advice and guidance on the practical applications of this technology, as well as longer-term strategies for scaling AI as the technology grows and matures.”

ISG Research forecasts the global market for AI-related managed services should reach $175 billion by 2030, Connors said.

Organizations already working with ISG on AI engagements include a global hospitality and entertainment company, a major U.S. manufacturer, two major global insurance companies, and a U.S. state government, with many others in discussions with the firm about advancing their AI agenda.

“ISG has always been at the forefront of guiding our clients through the complexities of adopting technology at scale,” said Steve Hall, ISG president and newly appointed as the firm’s first chief AI officer. “Our expansion into applied AI strategy and advisory is our next great leap forward, ensuring businesses can harness AI to drive unprecedented value into every aspect of their operations.”

Hall noted clients trust ISG for its independent advice and long-held expertise in technology sourcing and governance. “Typical of the feedback we’re getting from our clients is this statement: ‘We wanted to get ISG in right at the start of our journey so we can cut through the hype and do this right the first time. This is moving so fast we need to avoid any missteps.’”

ISG’s Applied AI Advisory services help clients assess their AI readiness, identify practical use cases, experiment with proofs of concept, create an AI strategy, and establish a business case for investment. ISG also helps clients select the right business partners and build a cognitive infrastructure to support AI at scale. Finally, ISG provides training and organizational change management, a strategy realization office, and governance through a proprietary AI control plane to help clients mitigate risk and maximize ROI from their AI investments.

ISG was the first sourcing advisory firm to establish a reference architecture for applied Generative AI when it published a September 2023 global study of enterprise use cases. An analysis of the use cases shows AI can lower the cost of IT operations by 30 to 58 percent.

The use cases range from personalizing customer experiences at scale and optimizing supply chain operations to enhancing decision-making through predictive analytics and pioneering the development of new products and services.

The ISG study found that 85 percent of enterprises believe investment in generative AI over the next two years is important, but only a small percentage are achieving tangible results today.

Hall said ISG is looking to help clients move beyond the hype and identify practical applications of AI that can lead to enterprise-wide adoption.

“Our goal is to empower businesses to define their AI-driven future, find the perfect partners to make it a reality, lead change in their organizations, and realize tangible value at a scale,” he said.

Hall noted that successful adoption of AI at scale will require the use of an “AI control plane” to oversee and manage the deployment of artificial intelligence systems.

“An AI control plane encompasses robust security measures to safeguard against data breaches and unauthorized access, ensuring the integrity and confidentiality of sensitive information,” said Hall.

“It also ensures AI operations adhere to legal and ethical standards and avoid biases, protecting users’ rights and promoting fairness, while providing oversight of AI-related expenditures and resource allocation, enabling efficient budget management and cost optimization.”

For more information about ISG’s Applied AI Advisory services, visit this webpage.

About ISG

ISG (Information Services Group) (Nasdaq: III) is a leading global technology research and advisory firm. A trusted business partner to more than 900 clients, including more than 75 of the world’s top 100 enterprises, ISG is committed to helping corporations, public sector organizations, and service and technology providers achieve operational excellence and faster growth. The firm specializes in digital transformation services, including automation, cloud and data analytics; sourcing advisory; managed governance and risk services; network carrier services; strategy and operations design; change management; market intelligence and technology research and analysis. Founded in 2006, and based in Stamford, Conn., ISG employs more than 1,600 digital-ready professionals operating in more than 20 countries—a global team known for its innovative thinking, market influence, deep industry and technology expertise, and world-class research and analytical capabilities based on the industry’s most comprehensive marketplace data. For more information, visit www.isg-one.com.

Source: Information Services Group, Inc.

View all news

Release – Kratos and Rancher Government Solutions Announce Strategic Partnership to Enable Customers to Seamlessly Deploy and Scale Virtual Ground Systems Using Kratos’ OpenSpace® Software Platform

Posted on by aweinsoff@channelchek.com

Research News and Market Data on KTOS

January 4, 2024 at 8:00 AM EST

First-to-Market OpenSpace Platform is a Software-Based Networking Solution that Connects Space to the Dynamic Ground, Supporting Multiple Satellites, Orbits, Payloads and Services

SAN DIEGO, Jan. 04, 2024 (GLOBE NEWSWIRE) — Kratos Defense & Security Solutions, Inc. (Nasdaq: KTOS), a technology company in Defense, National Security and Global Markets and Rancher Government Solutions (RGS), the leading provider of enterprise Kubernetes management solutions to the U.S. Government, announced today a strategic partnership to enable customers to seamlessly deploy and scale virtual ground systems using Kratos’ software-based OpenSpace® Platform.

With increasingly complex and dynamic satcom and Earth Observation missions, satellite operators and government agencies are transitioning from fixed and proprietary hardware to flexible and scalable generic compute-based cloud environments. This enables a virtualized and software-defined ground system like Kratos’ OpenSpace Platform to more cost effectively and securely support multiple missions simultaneously, deliver services faster and streamline operations.

Today, customers leverage a range of computing environments from bare metal, virtual machines to the cloud, making the deployment of software-based ground systems more complex and time consuming. Working together, Kratos and Rancher Government Solutions have enhanced the ability of the OpenSpace Platform, the first commercially available, fully virtualized and software-defined satellite ground system to be deployed more easily across customer environments.

“With Rancher, the OpenSpace Platform deploys its virtual functions including modems, channelizers, combiners, and more, as Kubernetes-based containerized software applications that act as independent and portable computing environments that can run and scale on any infrastructure,” said Brandon Gulla, Chief Technology Officer at RGS. “We are proud to be working with Kratos to support this truly transformational platform that will free satellite operators from proprietary hardware architectures and move to software-defined, flexible and extensible virtual platforms.”

By the nature of it being software-defined and containerized, the OpenSpace Platform is already much faster, and more flexible to deploy than traditional hardware-based satellite ground systems. As customer demands grow, the software-based OpenSpace Platform can reconfigure on the fly and deploy new services automatically and cost effectively in minutes. Software containers can be spun up and down and scaled on demand elastically using a single management interface from the Rancher Platform.

“Rancher serves as the Kubernetes management technology that supports the OpenSpace Platform’s ability to automate the deployment, scaling, and management of our containerized workloads,” said Anthony Semiao, Chief Solutions Architect of the OpenSpace Platform. “The combined technologies support hybrid and multi-cloud environments enabling OpenSpace customers to run in the data center and cloud environment of their choice such as Google, Amazon or Microsoft and to easily switch from one cloud provider to another.”

About Kratos OpenSpace
Kratos’ OpenSpace family of solutions enables the digital transformation of satellite ground systems to become a more dynamic and powerful part of the space network. OpenSpace® is the industry’s only commercially available digital transformation solution that enables operators of satellites, Ground Systems-as-a-Service (GSaaS) providers, teleports and others in the satellite services supply chain to capitalize on dynamic ground capabilities. The OpenSpace family consists of three product lines: OpenSpace SpectralNet for converting satellite RF signals to be used in digital environments; OpenSpace quantum products, which are virtual versions of traditional hardware components; and the OpenSpace Platform, the first commercially available, fully orchestrated, software-defined ground system. These three OpenSpace lines enable satellite operators and other service providers to implement digital operations at their own pace and in ways that meet their unique mission goals and business models. For more information about the OpenSpace family, visit www.KratosDefense.com/OpenSpace.

About Kratos Defense & Security Solutions
Kratos Defense & Security Solutions, Inc. (NASDAQ: KTOS) is a technology, products, system and software company addressing the defense, national security, and commercial markets. Kratos makes true internally funded research, development, capital and other investments, to rapidly develop, produce and field solutions that address our customers’ mission critical needs and requirements. At Kratos, affordability is a technology, and we utilize proven, leading edge approaches and technology, not unproven bleeding edge approaches or technology, with Kratos’ approach reducing cost, schedule and risk, and enabling us to be first to market with cost effective solutions. Kratos is known as the innovative disruptive change agent in the industry, a company that is an expert in designing products and systems up front for successful rapid, large quantity, low cost future manufacturing and as a competitive differentiator to our large traditional prime system integrator partners and also to our government and commercial customers. Kratos’ primary business areas include, virtualized ground systems for satellites and space vehicles including software for command & control (C2) and telemetry, tracking and control (TT&C), jet powered unmanned aerial drone systems, hypersonic vehicles and rocket systems, propulsion systems for drones, missiles, loitering munitions, supersonic systems, space craft and launch systems, C5ISR and microwave electronic products for missile, radar, missile defense, space, satellite, counter UAS, directed energy, communication and other systems, and virtual & augmented reality training systems for the warfighter. For more information, visit www.KratosDefense.com.

About Ranger
Rancher Government Solutions (RGS) is specifically designed to address the unique security and operational needs of the U.S. Government and military as it relates to application modernization, containers, and Kubernetes.

Rancher is a complete open source software stack for teams adopting containers. It addresses the operational and security challenges of managing multiple Kubernetes clusters at scale, while providing DevOps teams with integrated tools for running containerized workloads.

RGS supports all Rancher products with U.S. based American citizens who are currently supporting programs across the Department of Defense, Intelligence Community, and civilian agencies. From more information, visit www.ranchergovernment.com

Notice Regarding Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Kratos and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Kratos undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Kratos believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Kratos in general, see the risk disclosures in the Annual Report on Form 10-K of Kratos for the year ended December 25, 2022, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the SEC by Kratos.

Kratos Press Contact:
Yolanda White
858-812-7302 Direct

Kratos Investor Information:
877-934-4687
investor@kratosdefense.com

Rancher Government Press Contact:
Don Poole
(844) 747-7779
don.poole@ranchergovernment.com

Source: Kratos Defense & Security Solutions, Inc.

Release – Harte Hanks Extends Line of Credit with Texas Capital Bank

Posted on by aweinsoff@channelchek.com

Research News and Market Data on HHS

Extends Existing Line of Credit by Six Months

CHELMSFORD, MA / ACCESSWIRE / January 4, 2024 / Harte Hanks, Inc. (NASDAQ:HHS), a leading global customer experience company focused on bringing companies closer to customers for 100 years, today announced that the company has extended its $25 million secured revolving line of credit with Texas Capital Bank for an additional six (6) month term, beyond its original maturity date in December, 2024. The revised loan agreement, which now matures at the end of June, 2025, will enhance the Company’s financial flexibility and provide the Company with operational stability over this extended term.

The Company intends to use the credit facility for working capital and to create growth opportunities by investing in and enhancing client offerings.

“Texas Capital continues to be an important partner for Harte Hanks, and we are gratified in their confidence to extend our line of credit,” commented Kirk Davis, Harte Hanks’ Chief Executive Officer. “Having launched our transformation plan, Elevate, in Q3 of 2023, this successful extension supports our growth and transformation initiatives for the future.”

About Harte Hanks:

Harte Hanks (NASDAQ:HHS) is a leading global customer experience company whose mission is to partner with clients to provide them with CX strategy, data-driven analytics and actionable insights combined with seamless program execution to better understand, attract and engage their customers.

Using its unparalleled resources and award-winning talent in the areas of Customer Care, Fulfillment and Logistics, and Marketing Services, Harte Hanks has a proven track record of driving results for some of the world’s premier brands, including HBOMax, GlaxoSmithKline, Unilever, Pfizer, Volvo, Ford, FedEx, Midea, Sony and IBM among others. Headquartered in Chelmsford, Massachusetts, Harte Hanks has over 2,500 employees in offices across the Americas, Europe, and Asia Pacific.

For more information, visit hartehanks.com

As used herein, “Harte Hanks” or “the Company” refers to Harte Hanks, Inc. and/or its applicable operating subsidiaries, as the context may require. Harte Hanks’ logo and name are trademarks of Harte Hanks, Inc.

Cautionary Note Regarding Forward-Looking Statements:

Our press release and related earnings conference call contain “forward-looking statements” within the meaning of U.S. federal securities laws. All such statements are qualified by this cautionary note, provided pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements other than historical facts are forward-looking and may be identified by words such as “may,” “will,” “expects,” “believes,” “anticipates,” “plans,” “estimates,” “seeks,” “could,” “intends,” or words of similar meaning. These forward-looking statements are based on current information, expectations and estimates and involve risks, uncertainties, assumptions and other factors that are difficult to predict and that could cause actual results to vary materially from what is expressed in or indicated by the forward-looking statements. In that event, our business, financial condition, results of operations or liquidity could be materially adversely affected and investors in our securities could lose part or all of their investments. These risks, uncertainties, assumptions and other factors include: (a) local, national and international economic and business conditions, including (i) the outbreak of diseases, such as the COVID-19 coronavirus, which has curtailed travel to and from certain countries and geographic regions, created supply chain disruption and shortages, disrupted business operations and reduced consumer spending, (ii) market conditions that may adversely impact marketing expenditures, (iii) the impact of the Russia/Ukraine conflict on the global economy and our business, including impacts from related sanctions and export controls and (iv) the impact of economic environments and competitive pressures on the financial condition, marketing expenditures and activities of our clients and prospects; (b) the demand for our products and services by clients and prospective clients, including (i) the willingness of existing clients to maintain or increase their spending on products and services that are or remain profitable for us, and (ii) our ability to predict changes in client needs and preferences; (c) economic and other business factors that impact the industry verticals we serve, including competition and consolidation of current and prospective clients, vendors and partners in these verticals; (d) our ability to manage and timely adjust our facilities, capacity, workforce and cost structure to effectively serve our clients; (e) our ability to improve our processes and to provide new products and services in a timely and cost-effective manner though development, license, partnership or acquisition; (f) our ability to protect our facilities against security breaches and other interruptions and to protect sensitive personal information of our clients and their customers; (g) our ability to respond to increasing concern, regulation and legal action over consumer privacy issues, including changing requirements for collection, processing and use of information; (h) the impact of privacy and other regulations, including restrictions on unsolicited marketing communications and other consumer protection laws; (i) fluctuations in fuel prices, paper prices, postal rates and postal delivery schedules; (j) the number of shares, if any, that we may repurchase in connection with our repurchase program; (k) unanticipated developments regarding litigation or other contingent liabilities; (l) our ability to complete anticipated divestitures and reorganizations, including cost-saving initiatives; (m) our ability to realize the expected tax refunds; and (n) other factors discussed from time to time in our filings with the Securities and Exchange Commission, including under “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2022 which was filed on March 31, 2023. The forward-looking statements in this press release and our related earnings conference call are made only as of the date hereof, and we undertake no obligation to update publicly any forward-looking statement, even if new information becomes available or other events occur in the future.

Investor Relations Contact:

Rob Fink or Tom Baumann
646.809.4048 / 646.349.6641
FNK IR
HHS@fnkir.com

SOURCE: Harte Hanks, Inc.



View the original press release on accesswire.com

Release – Cocrystal Pharma Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investigational Candidates

Posted on by aweinsoff@channelchek.com

Research News and Market Data on COCP

JANUARY 04, 2024

BOTHELL, Wash., Jan. 04, 2024 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) provides an update on the clinical development of its oral first-in-class pan-norovirus and pan-coronavirus dual protease inhibitor CDI-988 and its oral PB2 inhibitor CC-42344 for the treatment of pandemic and seasonal influenza A. CDI-988 and CC-42344 were specifically designed and developed using Cocrystal’s unique structure-based drug discovery technology platform to be effective on a broad range of viruses causing these diseases.

“We are encouraged that the preliminary data of the ongoing Phase 2a and Phase 1 studies showed CC-42344 and CD-988 were well-tolerated with favorable safety profiles,” said Sam Lee, Ph.D., Cocrystal’s President and co-CEO. “We see great promise with both of these drug candidates as potential effective oral treatments for highly contagious, pandemic viruses, while also providing significant market opportunities for Cocrystal.”

CDI-988 targets a highly conserved region in the active site of the main 3CL protease required for viral RNA replication for pandemic norovirus and coronaviruses, including SARS-CoV-2. CDI-988 is being evaluated for safety and pharmacokinetics in a randomized, double-blinded, placebo-controlled Phase 1 study in healthy subjects being conducted in Australia. The Company reports favorable preliminary data from the single-ascending dose cohorts of the clinical study. Cocrystal expects to report topline results from the Phase 1 study this year.

CC-42344 binds to a highly conserved PB2 site of the influenza A polymerase complex and exhibits a novel mechanism of action that inhibits viral replication. A randomized, double-blind, placebo-controlled Phase 2a clinical study with CC-42344 is underway in the United Kingdom. The Company reports favorable tolerability and safety in the first cohort of the Phase 2a influenza A challenge study and expects to report topline results from the Phase 2a clinical study this year. In 2022 Cocrystal reported favorable safety and tolerability results in the healthy volunteer Phase 1 study with CC-42344 conducted in Australia.

About Norovirus

Although norovirus is a worldwide public health problem, there are no effective treatments or vaccines. Norovirus afflicts an estimated 685 million people annually at an estimated societal cost of $60 billion. About 200 million cases are seen among children under 5 years old, leading to an estimated 50,000 child deaths every year, mostly in developing countries, according to the Centers for Disease Control and Prevention (CDC). CDI-988 in vitro studies showed potent broad-spectrum antiviral activity against a panel of pandemic GII.4 norovirus proteases, which have caused the majority of norovirus outbreaks worldwide since 2002, and a favorable pharmacokinetic property targeting the gastrointestinal tract.

About COVID-19
COVID-19 hospitalizations have recently increased in the U.S. with the new JN.1 variant responsible for about 20% of these cases. Driven by the anticipated emergence of new COVID-19 variants, the global COVID-19 therapeutics market is estimated to exceed $16 billion by the end of 2031. The ability of someone with no symptoms to transmit infection to another person has heightened the public health challenge of COVID-19. CDI-988 exhibited superior in vitro potency against SARS-CoV-2 with activity maintained against variants of concern. By targeting the viral replication protease, Cocrystal believes it is possible to develop an effective treatment for all coronaviruses, including COVID-19 and its variants, as well as for Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS).

About Seasonal Influenza
Each year there are approximately 1 billion cases of seasonal influenza worldwide, with 3-5 million severe illnesses and up to 650,000 deaths, according to the World Health Organization. On average about 8% of the U.S. population contracts influenza each season. In addition to the health risk, influenza is responsible for approximately $10.4 billion in direct costs for hospitalizations and outpatient visits for adults in the U.S. annually.

About Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2) noroviruses and hepatitis C viruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the promise and potential of the two product candidates, the clinical development of CC-42344 as a product candidate for oral antiviral inhibitor for the treatment of pandemic and seasonal influenza A and the Phase 2a study for such product candidate, CC-988 as a product candidate for dual oral antiviral inhibitor for the treatment of coronavirus and norovirus and the Phase 1 study for such product candidate, the potential efficacy and clinical benefits of, and market for, such product candidates, and the expected results and topline data from these clinical trials in 2024. The words “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events. Some or all of the events anticipated by these forward-looking statements may not occur. Important factors that could cause actual results to differ from those in the forward-looking statements include, but are not limited to, risks relating to our ability to proceed with the studies including recruiting volunteers and procuring materials for such studies by our clinical research organizations and vendors, and the results of such studies. Further information on our risk factors is contained in our filings with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2022. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

Investor Contact:
LHA Investor Relations
Jody Cain
310-691-7100
jcain@lhai.com

Media Contact:
JQA Partners
Jules Abraham
917-885-7378
Jabraham@jqapartners.com

# # #

Source: Cocrystal Pharma, Inc.

Released January 4, 2024

Release – ZyVersa Therapeutics Announces Equity Research Coverage Initiated by Noble Capital Markets

Posted on by aweinsoff@channelchek.com

Research News and Market Data on ZVSA

Jan 4, 2024

PDF Version

  • ZyVersa is developing two proprietary product platforms targeting renal and inflammatory diseases.
  • Cholesterol Efflux MediatorTM VAR 200, designed to ameliorate renal lipid accumulation that damages the kidneys’ filtration system, leading to chronic kidney disease and its progression.
  • Inflammasome ASC Inhibitor IC 100, designed to inhibit multiple inflammasome pathways to attenuate initiation and perpetuation of damaging inflammation pathogenic in numerous inflammatory diseases.

WESTON, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) — ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseases who have unmet medical needs, announces that Noble Capital Markets has initiated company-sponsored equity research coverage. To obtain a copy of the full report authored by Noble Capital Markets’ Senior Research Analyst Robert LeBoyer, as well as news and advanced market data on ZyVersa Therapeutics, please go to Channelchek.com.

About ZyVersa Therapeutics, Inc.

ZyVersa is a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop first-in-class drugs. Our focus is on patients with renal or inflammatory diseases who have significant unmet medical needs. Our development pipeline includes clinical stage Cholesterol Efflux MediatorTM VAR 200 in development to alleviate damaging accumulation of cholesterol and lipids in the kidneys’ filtration system. The lead indication is treatment of rare kidney disease, focal segmental glomerulosclerosis. VAR 200 has potential to treat other kidney diseases, including Alport syndrome and diabetic kidney disease. ZyVersa’s pipeline also includes proprietary inflammasome ASC inhibitor IC 100 that blocks initiation and perpetuation of damaging inflammation associated with a multitude of inflammatory diseases. IC 100 has potential to treat many different CNS and other inflammatory diseases. For more information, please visit www.zyversa.com.

About Noble Capital Markets

Noble Capital Markets, Inc. was incorporated in 1984 as a full-service SEC / FINRA registered broker-dealer, dedicated exclusively to serving underfollowed small/microcap companies through investment banking, wealth management, trading & execution, and equity research activities. Over the past 37 years, Noble has raised billions of dollars for these companies and published more than 45,000 equity research reports. For more information, please visit www.noblecapitalmarkets.com or email: contact@noblecapitalmarkets.com.

About Channelchek

Channelchek (.com) is a comprehensive investor-centric portal – featuring more than 6,000 emerging growth companies – that provides advanced market data, independent research, balanced news, video webcasts, exclusive c-suite interviews, and access to virtual road shows. The site is available to the public at every level without cost or obligation. Research on Channelchek is provided by Noble Capital Markets, Inc., an SEC / FINRA registered broker-dealer since 1984. For more information, go to www.channelchek.com or email: contact@channelchek.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements contained in this press release regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These include statements regarding management’s intentions, plans, beliefs, expectations, or forecasts for the future, and, therefore, you are cautioned not to place undue reliance on them. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. ZyVersa Therapeutics, Inc (“ZyVersa”) uses words such as “anticipates,” “believes,” “plans,” “expects,” “projects,” “future,” “intends,” “may,” “will,” “should,” “could,” “estimates,” “predicts,” “potential,” “continue,” “guidance,” and similar expressions to identify these forward-looking statements that are intended to be covered by the safe-harbor provisions. Such forward-looking statements are based on ZyVersa’s expectations and involve risks and uncertainties; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including ZyVersa’s plans to develop and commercialize its product candidates, the timing of initiation of ZyVersa’s planned preclinical and clinical trials; the timing of the availability of data from ZyVersa’s preclinical and clinical trials; the timing of any planned investigational new drug application or new drug application; ZyVersa’s plans to research, develop, and commercialize its current and future product candidates; the clinical utility, potential benefits and market acceptance of ZyVersa’s product candidates; ZyVersa’s commercialization, marketing and manufacturing capabilities and strategy; ZyVersa’s ability to protect its intellectual property position; and ZyVersa’s estimates regarding future revenue, expenses, capital requirements and need for additional financing. A discussion of these and other factors, including risks and uncertainties with respect to ZyVersa, is set forth in ZyVersa’s filings with the Securities and Exchange Commission, including ZyVersa’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q.

New factors emerge from time-to-time, and it is not possible for ZyVersa to predict all such factors, nor can ZyVersa assess the impact of each such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements included in this press release are based on information available to ZyVersa as of the date of this press release. ZyVersa disclaims any obligation to update such forward-looking statements to reflect events or circumstances after the date of this press release, except as required by applicable law.

This press release does not constitute an offer to sell, or the solicitation of an offer to buy, any securities.

Corporate and IR Contact
Karen Cashmere
Chief Commercial Officer
kcashmere@zyversa.com
786-251-9641

Media Contacts
Casey McDonald
cmcdonald@tiberend.com
646-577-8520

Dave Schemelia
Dschemelia@tiberend.com
609-468-9325

Release – V2X wins $190M U.S. Army Contract to Enhance Warfighter Readiness in Middle East Operations

Posted on by aweinsoff@channelchek.com

Research News and Market Data on VVX

January 4, 2024

MCLEAN, Va., Jan. 4, 2024 /PRNewswire/ — V2X, Inc. (NYSE: VVX) was awarded a $190 million contract from the U.S. Army as part of the United States Army Central Command (USARCENT) Training and Range Operations Maintenance Services Contract (ATROMS). The competitively bid firm-fixed-price contract will span five-years, continuing V2X’s support to USARCENT’s mission in Kuwait as well as other locations within the U.S. Central Command (USCENTCOM) Area of Responsibility (AOR). V2X will provide training support services as well as instruction, operation, and maintenance of Training Aids, Devices, Simulators and Simulations (TADSS). These services are crucial in expanding the USARCENT ability to not only maintain but enhance warfighter readiness.

“With this significant contract award, V2X reaffirms its commitment to bolstering the U.S. Army’s training and operational capabilities in dynamic environments,” said Chuck Prow, President and Chief Executive Officer at V2X. “Our proven expertise and dedication underscore our mission to empower the warfighter’s readiness for any challenge.”

Given the challenging dynamics of the Middle East and USCENTCOM AOR landscapes, the contract facilitates the rapid deployment of a multitude of Live, Virtual, and Constructive (LVC) resources, effectively enhancing the strategic positioning of USARCENT.

About V2X

V2X builds smart solutions designed to integrate physical and digital infrastructure – from base to battlefield – by aligning people, actions, and outputs. Formed by the merger of Vectrus and Vertex, we bring a combined 120 years of successful mission support. Our lifecycle solutions improve security, streamline logistics, and enhance readiness.

The Company delivers a comprehensive suite of integrated solutions across the operations and logistics, aerospace, training, and technology markets to national security, defense, civilian, and international clients. Our global team of approximately 15,000 employees brings innovation to every point in the mission lifecycle, from preparation to operations, to sustainment, as it tackles the most complex challenges with agility, grit, and dedication.

Media Contact
Angelica Spanos Deoudes
Senior Media Strategist
Communications@goV2X.com
571-338-5195

Investor Contact
Mike Smith, CFA
Vice President, Treasury, Corporate Development and Investor Relations
IR@goV2X.com
719-637-5773

View original content to download multimedia:https://www.prnewswire.com/news-releases/v2x-wins-190m-us-army-contract-to-enhance-warfighter-readiness-in-middle-east-operations-302025734.html

SOURCE V2X, Inc.

Release – Snail Games’ ARKade Ambassador Program Reshapes Gaming Connections

Posted on by aweinsoff@channelchek.com

Research News and Market Data on SNAL

January 3, 2024 at 4:06 PM EST

A Community Journey, 186M+ Minutes Strong

CULVER CITY, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) — Snail, Inc. (Nasdaq: SNAL) (“Snail” or “the Company”), a leading, global independent developer and publisher of interactive digital entertainment, introduced the ARKade Ambassador Program, an influencer community initiative designed to express gratitude to and foster connections among creators within the ARK community, alongside the launch of ARK Survival Ascended on Steam. The distinctive perspectives and insightful contributions of these creators have played a pivotal role in uncovering community insights and generating genuine feedback. This involvement has led to an impressive viewership of 186,509,155+ minutes of ARKade content, establishing a robust and captivated audience.

The success of ARKade has been further enhanced by the support of notable sponsors such as MadCatz, Streamlabs, and Glytch, who have generously sponsored ARKade prizes for streamers. These strategic collaborations not only elevate the experience for content creators but also opens the door for future collaborative opportunities as the ARK franchise continues to grow.

“We are thrilled with the enthusiastic response ARKade has received from both content creators and sponsors,” Jim Tsai, Chief Executive Officer of Snail, Inc. “The numbers speak for themselves, and the success of the ARKade Ambassador Program is a testament to the engaging and immersive nature of ARK Survival Ascended.”

Looking ahead, Snail Games is excited to build on this momentum, fostering new connections, and expanding collaborations with creators and brands as they continue to evolve the ARK franchise.

Checkout our ARKade Sponsors:
http://www.madcatz.com/
https://glytchenergy.com/
https://streamlabs.com/

About Snail, Inc.- https://www.snailgamesusa.com/
Snail is a leading, global independent developer and publisher of interactive digital entertainment for consumers around the world, with a premier portfolio of premium games designed for use on a variety of platforms, including consoles, PCs and mobile devices.

Forward-Looking Statements
This press release contains statements that constitute forward-looking statements. Many of the forward-looking statements contained in this press release can be identified by the use of forward-looking words such as “anticipate,” “believe,” “could,” “expect,” “should,” “plan,” “intend,” “may,” “predict,” “continue,” “estimate” and “potential,” or the negative of these terms or other similar expressions. Forward-looking statements appear in a number of places in this press release and include, but are not limited to, statements regarding Snail’s intent, belief or current expectations. These forward-looking statements include information about possible or assumed future results of Snail’s business, financial condition, results of operations, liquidity, plans and objectives. The statements Snail makes regarding the following matters are forward-looking by their nature: growth prospects and strategies; launching new games and additional functionality to games that are commercially successful; expectations regarding significant drivers of future growth; its ability to retain and increase its player base and develop new video games and enhance existing games; competition from companies in a number of industries, including other game developers and publishers and both large and small, public and private Internet companies; its relationships with third-party platforms; expectations for future growth and performance; and assumptions underlying any of the foregoing.

Contacts:

Investors:
investors@snail.com

Press:
Media@snailgamesusa.com